The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
 
Itamar Sela
Employment - Oncohost
Leadership - Oncohost
Stock and Other Ownership Interests - Oncohost
Travel, Accommodations, Expenses - Oncohost
 
Coren Lahav
Employment - Oncohost; Sanofi (I)
Stock and Other Ownership Interests - Oncohost
Travel, Accommodations, Expenses - Oncohost
 
Gil Lowenthal
Employment - Oncohost
Stock and Other Ownership Interests - Oncohost
 
Michal Harel
Employment - Oncohost
Stock and Other Ownership Interests - Oncohost
Travel, Accommodations, Expenses - Oncohost
 
Yehonatan Elon
Employment - Oncohost
Leadership - Oncohost
Stock and Other Ownership Interests - Oncohost
Patents, Royalties, Other Intellectual Property - Plasma proteomics based predictor for response to immune checkpoint inhibitors
 
Ben Yellin
Employment - Oncohost
Stock and Other Ownership Interests - Oncohost
Travel, Accommodations, Expenses - Oncohost
 
Adam P. Dicker
Stock and Other Ownership Interests - Oncohost
Consulting or Advisory Role - Aptar Pharma; Blue Spark Technologies; CVS; EmpiricaLab; Hengrui Pharmaceutical; IBA; Imagene AI; Janssen; Oncohost; Onconova Therapeutics; Orano Med; SBR Biotechnologies
Patents, Royalties, Other Intellectual Property - We recently filed a patient "DOPED BEO COMPOUNDS FOR OPTICALLY STIMULATED LUMINESCENCE (OSL) AND THERMOLUMINESCENCE (TL) RADIATION DOSIMETRY" (Inst)
Travel, Accommodations, Expenses - Oncohost
Other Relationship - European Commission
(OPTIONAL) Uncompensated Relationships - Dreamit Ventures; Google
 
Ruth Halaban
No Relationships to Disclose
 
Jenn Marte
No Relationships to Disclose
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Asher Biotherapeutics; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Normunity; Oncohost; Repertoire Immune Medicines; Rootpath
Consulting or Advisory Role - Adagene; Adaptimmune; Agenus; Alligator Bioscience; AnaptysBio; AstraZeneca/MedImmune; Biond Biologics; BioNTech; Bristol-Myers Squibb; Dragonfly Therapeutics; Genocea Biosciences; Gilead Sciences; immunocore; Innate Pharma; Iovance Biotherapeutics; ITeos Therapeutics; Jazz Pharmaceuticals; Kadmon; Kanaph Therapeutics; Merck; Molecular Partners; Numab; Ocellaris Pharma; OncoSec; Pfizer; Pierre Fabre; PIOtx; Pliant; Regeneron; Sapience Therapeutics; Seagen; Simcha Therapeutics; Simcha Therapeutics; ST Cube; Targovax; Tessa Therapeutics; Turnstone Bio; Verastem; Xilio Therapeutics
Other Relationship - CEC Oncology; Physicans' Education Resource
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Marengo Therapeutics (Inst); Merck (Inst); NextCure (Inst); PDS Biotechnology (Inst); Pfizer (Inst); Precigen (Inst); Syndax (Inst); Syntrix Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje